Back to Search Start Over

PARP Inhibitors in First-Line Therapy of Ovarian Cancer: Are There Any Doubts?

Authors :
Fortunato Ciardiello
Sara Centonze
A. Diana
Elisena Franzese
Ferdinando De Vita
Michele Orditura
Sandro Pignata
Franzese, E.
Diana, A.
Centonze, S.
Pignata, S.
De Vita, F.
Ciardiello, F.
Orditura, M.
Source :
Frontiers in Oncology, Frontiers in Oncology, Vol 10 (2020)
Publication Year :
2020
Publisher :
Frontiers Media SA, 2020.

Abstract

The standard of care for newly diagnosed advanced ovarian cancer (NADOC) is represented by surgical debulking followed by systemic platinum–taxanes combination chemotherapy. At the last European Society for Medical Oncology (ESMO) Congress, results from three trials testing three different poly-adenosine-diphosphate-ribose-polymerase (PARP) inhibitors (olaparib, niraparib, veliparib) in first-line therapy of OC have been presented. For the first time, these studies evaluated the efficacy of PARP inhibitors in this setting and the relative predictive biomarkers for patients' selection. The use of a PARP inhibitor is related with prolonged progression free survival (PFS) in the whole population of NADOC, although the magnitude of benefit varies widely among subgroups, highlighting the need to identify specific biological subtypes into clinical practice. In this minireview, we discuss the updated data available from clinical studies in this scenario.

Details

ISSN :
2234943X
Volume :
10
Database :
OpenAIRE
Journal :
Frontiers in Oncology
Accession number :
edsair.doi.dedup.....91d6650612adf22345d985dbbd5b1e7e
Full Text :
https://doi.org/10.3389/fonc.2020.00782